After a decade of innovation, the TPD field has its first drug approval in the form of Arvinas’ Veppanu. Combined with the recovering market of 2026, this clinical validation will […]

GLP-1s changed the treatment paradigm for obesity reaching new heights of efficacy. Now, as unmet need persists and the field looks beyond efficacy alone, momentum is building behind therapies that […]